Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the bioequivalence based on pharmacokinetics (PK) of a single 120 mg subcutaneous
dose of denosumab administered to healthy volunteers using denosumab CP4 or denosumab CP2
drug products.